Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis

Documenti analoghi

• Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
  di: Masanori Inoue, et al.
  Pubblicazione: (2026)
• Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy
  di: Chihiro Miwa, et al.
  Pubblicazione: (2025)
• Convergence to pushed fronts and the behavior of level sets in monostable reaction-diffusion equations
  di: Kiyono, Ryo
  Pubblicazione: (2026)
• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2025)
• Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2024)